Sector News

Stada agrees to compromise with activist investor on board reshuffle

May 13, 2016
Life sciences

German generic drugmaker Stada has agreed to a shareholder vote on proposed board changes after an activist investor had asked for a thorough overhaul, the company said on Friday.

Active Ownership Capital will now seek to replace three instead of five of Stada’s nine supervisory board members at its annual general meeting on June 9, and it is no longer asking for the removal of board Chairman Martin Abend.

Stada said in a statement it was agreeing to the compromise to avoid a pricey legal battle as well as the need to call an extraordinary meeting of shareholders.

Shares in Stada have surged about 11 percent this month on speculation that Active Ownership’s campaign could lead to the sale or break up of the company.

The Luxembourg-based investor, which has a 5 percent stake in the company, has said its push for a shareholder vote on the supervisory board is to add international healthcare expertise to help Stada realise its potential.

Active Ownership wants Klaus-Joachim Krauth, the former finance chief of Hexal and Athos; Ulrich Wandschneider, who until recently was chief executive of hospitals chain Asklepios Kliniken; and Active Ownership founding partner Klaus Roehrig on the supervisory board.

They would replace Eckhard Brueggemann, Arnold Hertzsch and Constantin Meyer.

By Arno Schuetze, Alexander Huebner and Maria Sheahan

Source: Reuters

Related News

September 22, 2020

GSK’s Zejula and AZ’s Lynparza leap toward broader EU approval

Life sciences

GlaxoSmithKline’s Zejula and AstraZeneca’s Lynparza have both moved towards EU approval in new indications after receiving positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human […]

September 22, 2020

Roche acquires Irish biotech firm Inflazome

Life sciences

Swiss pharma company Roche is set to acquire Irish biotech firm Inflazome for an upfront payment of $449m (€380m). In addition to the upfront payment, Inflazome is also eligible to […]

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]